OncoSil Medical Reports 44% Revenue Growth and FDA Approval in FY26
OncoSil Medical lifted revenues 44% in FY26 to $1.68 million and trimmed losses by 28% to $10.86 million, buoyed by key regulatory approvals including FDA HDE and Australian TGA listings. The company is poised for commercial launches in the US and Australia, with strong clinical data underpinning its growth.
- 43.9% revenue growth to $1.68 million
- 28.1% reduction in net loss to $10.86 million
- FDA Humanitarian Device Exemption approval for distal cholangiocarcinoma
- Australian TGA approval enables domestic commercial launch
- 53% unit sales growth and expanded European market presence
Regulatory Breakthroughs Unlock US and Australian Markets
OncoSil Medical (ASX:OSL) marked a pivotal year in FY26, securing landmark regulatory approvals that set the stage for commercial expansion in two major markets. In August 2026, the company clinched FDA Humanitarian Device Exemption (HDE) approval for its OncoSil™ device targeting distal cholangiocarcinoma, a rare bile duct cancer. This milestone opens the US market, estimated at around 1,000 patients annually, with a commercial launch planned for the first half of calendar 2027.
Earlier in May 2026, OncoSil also gained Therapeutic Goods Administration (TGA) approval in Australia, allowing the device's use for unresectable locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. This approval is the first of its kind for a Class III medical device targeting pancreatic tumors in Australia, a market with approximately 4,350 new cases each year. The company anticipates launching domestically in H1 2027.
Clinical Data Fuels Commercial Momentum and Market Confidence
OncoSil’s commercial progress is underpinned by a growing body of clinical evidence. The TRIPP-FFX trial, completed in FY26, met both co-primary endpoints, demonstrating encouraging safety and efficacy when OncoSil™ is combined with FOLFIRINOX chemotherapy. Presented at the prestigious ESMO GI 2026 congress, these results are expected to support regulatory submissions to extend the device’s CE Mark to align with current standard-of-care regimens, potentially expanding the eligible patient population in Europe.
The company also concluded the investigator-initiated PANCOSIL study, which established the safety and feasibility of CT-guided percutaneous delivery of OncoSil™, a less invasive administration route. Regulatory submissions to approve this delivery method are targeted for late 2026, broadening access to interventional radiologists and expanding market reach.
Independent clinical data from the Royal Adelaide Hospital further bolstered OncoSil’s profile, showing superior median overall survival of 22 months compared to 14 months with stereotactic body radiation therapy. Meanwhile, real-world evidence from the OSPREY registry continues to validate the device’s safety and efficacy in routine clinical practice.
European Expansion Anchored by Germany and Reimbursement Advances
Germany remains the company's most strategically important European market, with a potential addressable population of 2,000 to 3,000 patients annually. OncoSil has grown the number of hospitals eligible for NUB reimbursement and recently achieved its first successful treatment at Vivantes Neukölln Hospital in Berlin, one of Germany’s largest municipal hospitals.
Looking ahead, a G-BA sponsored clinical trial commencing in H2 2026 aims to unlock broader public hospital reimbursement across Germany. This trial could serve as a benchmark for reimbursement negotiations across Europe, accelerating adoption in other member states. Additional progress in Italy and the UK is easing procurement and market access barriers, supporting a scalable commercial model.
Financial Discipline Supports Growth and Manufacturing Scale-Up
OncoSil reported a 43.9% increase in revenue to $1.68 million and a 28.1% reduction in net loss to $10.86 million for FY26. Unit sales rose 53%, reflecting growing physician adoption. The company ended the year with $6.5 million in cash, bolstered by an $8 million capital raise in February 2026 backed by cornerstone investors Pengana Capital Group and Regal Funds Management.
Investment in research and development remained significant at $3.8 million, focusing on pivotal clinical trials now entering close-out phases. Management identified annualised cost savings of $3.4 million to $3.9 million for FY27, aiming to leverage operating efficiencies as revenue scales.
Meanwhile, OncoSil is advancing completion of its Macquarie Park manufacturing facility in Sydney, expected to enhance gross margins and supply chain resilience. The facility has successfully completed hot production test runs and is poised to support both domestic and export demand.
Board Refresh and Aligned Leadership Incentives
The Board saw key changes in FY26 with Dr Thomas Duthy appointed Non-Executive Chairman and Lel Smits joining as Non-Executive Director. Both directors elected to receive fees in shares, aligning their interests with shareholders. CEO Nigel Lange also converted 10% of his salary into shares, underscoring management’s commitment to shareholder value creation during this critical commercialisation phase.
Corporate governance practices continue to be reviewed against ASX standards to support the company’s evolving strategic priorities.
Bottom Line?
OncoSil’s FY26 results and regulatory approvals position it at a commercial inflection point, but execution on US and Australian launches and European reimbursement trials will be critical to sustaining momentum.
Questions in the middle?
- How quickly will OncoSil convert FDA HDE approval into meaningful US commercial sales?
- Will the G-BA clinical trial in Germany unlock broader European reimbursement and adoption?
- Can OncoSil scale manufacturing efficiently to meet anticipated global demand while improving margins?
